Document:

EXHIBIT 10.1

 

AMENDMENT NO. 2 TO LICENSE AGREEMENT

 

This Amendment
No. 2 to License Agreement (this “Amendment”), dated as of December 27, 2022, is made by and between Relmada
Therapeutics, Inc., a Nevada corporation (“Licensee”) and Dr. Charles E. Inturrisi, an individual, and Dr.
Paolo Manfredi, an individual, jointly and severally (collectively, “Licensor”).

 

Whereas,
the parties have previously entered into that certain License Agreement dated as of January 16, 2018, which was amended by Amendment No.
1 to License Agreement dated as of December 2, 2019 (as so amended, the “License Agreement”) (capitalized terms used
herein but not otherwise defined shall have the meaning ascribed to such terms in the License Agreement); and

 

Whereas,
the parties now desire to further amend the License Agreement as set forth herein.

 

Now,
Therefore, in consideration of the foregoing, of the mutual promises set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:

 

ARTICLE
I

 

Amendment
of License Agreement

 

1.1.   Article
7, Section 7.1(a)(iii) is hereby amended to replace the date “December 31, 2022” with the date “December 31, 2027”.

 

1.2.    Article
7, Section 7.1(a)(iv) is hereby amended to replace the date “December 31, 2022” with the date “December 31, 2027”.

 

ARTICLE
II

 

General

 

2.1. Continuation.
Except as expressly modified in Article 1, the License Agreement shall remain in full force and effect.

 

2.2. Governing Law.
This Amendment shall be governed by, and construed in accordance with (A) the laws of the United States, in respect to trademark and patent
issues, except that the scope and validity of any foreign Patent or trademark shall be governed by the applicable laws of the country
of the Patent or trademark, and (B) in all other respects, including as to validity (except for patent and trademark issues), interpretation
and effect, by the laws of the State of New York without giving effect to the conflict of laws rules thereof. The parties hereby consent
to the sole and exclusive jurisdiction of the courts of the state of New York, in the county of New York, or the United States Federal
District Court for the Southern District of New York for purposes of any action or proceeding brought by either of them on or in connection
with this Amendment on any alleged breach thereof and waive any right to assert any rights or defenses within any other jurisdiction or
to require that litigation regarding this Amendment take place elsewhere. Notwithstanding the foregoing, either party may apply to any
court of competent jurisdiction for injunctive relief or any other appropriate relief.

 

2.3. Headings. The
section headings contained in this Amendment are set forth for the convenience of the Parties only, do not form a part of this Amendment
and are not to be considered a part hereof for the purpose of construction or interpretation hereof, or otherwise.

 

2.4. Counterparts.
This Amendment may be executed and delivered in any number of counterparts including PDF, facsimile, or other electronic counterparts,
each of which will be an original, but all of which together will constitute one instrument.

 

2.5. Severability. In
the event any one or more of the provisions of this Amendment should for any reason be held by any court or authority having jurisdiction
over this Amendment or any of the Parties to be invalid, illegal or unenforceable, such provision or provisions shall be validly reformed
to as nearly as possible approximate the intent of the Parties and, if unreformable, shall be divisible and deleted in such jurisdiction;
elsewhere, this Amendment shall not be affected so long as the Parties are still able to realize the principal benefits bargained for
in this Amendment.

 

[Remainder of Page Intentionally Left Blank]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have caused this Amendment to be duly executed as of the date first set forth above.

 

LICENSOR

 

	Dr. Charles E. Inturrisi and Dr. Paolo Manfredi 	 
	 	 
	/s/ Charles E. Inturrisi	 
	Dr. Charles E. Inturrisi	 
	 	 
	/s/ Paolo Manfredi	 
	Dr. Paolo Manfredi	 

 

LICENSEE

 

	Relmada Therapeutics, Inc.	 
	 	 	 
	By:	/s/ Sergio Traversa	 
	Name:	Sergio Traversa	 
	Title:	Chief Executive Officer	 

 

Signature
Page to Amendment No. 2 to

License
AgreementExhibit 10.1

 

Execution Version

 

AMENDMENT NO. 2 TO EQUITY SUPPORT AGREEMENT

 

This AMENDMENT NO. 2 TO THE EQUITY SUPPORT
AGREEMENT (this “Amendment”) is entered into as of December 27, 2022, by and between TH International Limited, a
Cayman Islands exempted company (the “Issuer”), and Shaolin Capital Partners Master Fund Ltd, MAP 214 Segregated
Portfolio, a segregated portfolio of LMA SPC, DS Liquid DIV RVA SCM LLC, and Shaolin Capital Partners SP, a segregated portfolio of
PC MAP SPC (each individually, a “Subscriber” and collectively, the “Subscribers”). Capitalized terms used
but not defined herein shall have the meanings ascribed to them under the Agreement (as defined below).

 

WHEREAS,
Shaolin Capital Management LLC and the Issuer entered into that certain Equity Support Agreement, dated March 8, 2022 (the “Equity
Support Agreement”).

 

WHEREAS,
Shaolin Capital Management LLC assigned all of its rights and obligations under the Equity Support Agreement to the Subscribers on May 25,
2022, pursuant to Section 14(e) of the Equity Support Agreement.

 

WHEREAS,
the Subscribers and the Issuer entered into that certain Amendment No. 1 to the Equity Support Agreement on July 28, 2022. The
term “Agreement” in this Amendment means the Equity Support Agreement, as assigned on May 25, 2022 and as amended as
of July 28, 2022, as described above.

 

WHEREAS,
the parties hereto understand that the Issuer intends to issue a press release and/or furnish to the SEC a current report on Form 6-K
stating the material terms of this Amendment on or before 9:00 a.m. Eastern Standard Time on December 28, 2022, if the Issuer
is advised by its legal counsel that such press release and/or Form 6-K is necessary.

 

WHEREAS,
the Issuer (i) acknowledges that (a) if it does not issue a press release and/or furnish to the SEC a current report on Form 6-K
stating the material terms of this Amendment on or before 9:00 a.m. Eastern Standard Time on December 28, 2022, it shall confirm
to the Subscribers that it represents and warrants that, to its knowledge, the Subscribers are not in possession of material, non-public
information relating to the Issuer and its securities no later than 9.00 a.m. Eastern Standard Time on December 28, 2022; and
(b) the Subscribers are not subject to a non-disclosure agreement with the Issuer; and (ii) consents to the Subscribers issuing
a press release stating the material terms of this Amendment.

 

WHEREAS,
the parties hereto wish to amend the Agreement as set out below:

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements herein contained,
and intending to be legally bound hereby, the parties hereto agree as follows:

 

		1.	Amendment to the Agreement.

 

		1.1	Amendment to the definition of “First Reference Price Commencement Date”.

 

The text ““First Reference Price
Commencement Date” shall mean the 85th calendar day immediately following the date of the Closing (as defined in the
Transaction Agreement.” is deleted in its entirety and replaced with:

 

““First Reference Price Commencement Date”
shall mean December 29, 2022, if such date is a VWAP Trading Day, or the next immediate VWAP Trading Day following December 29,
2022, if December 29, 2022 is not a VWAP Trading Day.”

 

    1 

     

    

 

		1.2	Amendment to the definition of “Reference Period”.

 

The text below is deleted in its entirety:

 

“Any Reference Period (other than an Accelerated
Reference Period) shall be extended by no more than six (6) VWAP Trading Days a maximum of one (1) time in any Reference
Period, as determined by the Calculation Agent, if (a) across such Reference Period the aggregate volume of Issuer Ordinary
Shares is fewer than 2,500,000 in total, as determined by the Calculation Agent by reference to the Bloomberg Page “SLCR
US <equity> HP”, it being understood that immediately following the Transaction Closing, such page is expected to
be replaced with “THCH US <equity> HP” (or its equivalent successor if such page is not available) and
(b) the Issuer has fulfilled its obligations in Section 7. For the avoidance of doubt, the maximum length of any Reference
Period, following an extension pursuant to the provisions in the immediately prior sentence, shall never be greater than thirty-one
(31) VWAP Trading Days, and during such extension, the provisions of Section 7 shall remain in force.”

 

		1.3	Amendment to the definition of “First Reference Period”.

 

The number “25” in the definition of “First
Reference Period” is replaced with the number “27”.

 

		1.4	Amendment to the definition of “Second Reference Period”.

 

The number “25” in the definition of “Second
Reference Period” is replaced with the number “30”.

 

		1.5	Amendment to the definition of “Third Reference Period”.

 

The number “25” in the definition of “Third
Reference Period” is replaced with the number “30”.

 

		1.6	Amendment to Section 13.

 

The text “For purposes of the preceding Section 13,”
that is after the word “Definitions: ” in Section 13 is replaced with “For the purposes of this Equity Support
Agreement”.

 

		1.7	Amendment to Section 17.

 

The text “(in each case in this clause (iv), solely
if receipt is confirmed, but excluding any automated reply, such as an out-of-office notification)” in Section 17 is deleted
in its entirety.

 

		2.	Miscellaneous.

 

2.1   Representations
and Warranties. Each party hereto hereby represents and warrants to each other party that:

 

(a)   It
has the power (corporate or otherwise) and authority to enter into, deliver and perform its obligations under this Amendment. The
execution, delivery and performance by it of this Amendment have been duly authorized and (1) will not conflict with or result
in a breach or violation of the terms or provisions of, or constitute a default under, (i) any indenture, mortgage, deed of
trust, loan agreement, lease, license or other agreement or instrument to which it or any of its subsidiaries is a party or by which
it or any of its subsidiaries is bound, or (ii) any law, statute, or any judgment, order, rule or regulation of any court
or other tribunal or of any governmental agency or body, domestic or foreign, having jurisdiction over it, and (2) will not
violate any provisions of its organizational documents.

 

(b)   Assuming
that this Amendment constitutes the valid and binding agreement of each other party, this Amendment constitutes the legal, valid and
binding agreement of such party, enforceable against it in accordance with its terms, except as may be limited or otherwise affected
by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the
rights of creditors generally, or (ii) principles of equity, whether considered at law or equity.

 

2.2   Representations
and Warranties of the Issuer. The Issuer hereby repeats the representations and warranties contained in Section 5(a), 5(e), 5(g),
5(l), 5(m), 5(n) and 5(q) of the Agreement as if such representations and warranties were made as of the date hereof.

 

    2 

     

    

 

2.3   Effect
of Amendment. This Amendment shall form a part of the Agreement for all purposes, and each party thereto and hereto shall be bound
hereby. From and after the execution of this Amendment by the parties hereto, any reference to the Agreement shall be deemed a
reference to the Agreement as amended hereby. This Amendment shall be deemed to be in full force and effect from and after the
execution of this Amendment by the parties hereto. Except as provided hereby, all of the representations, warranties, terms,
covenants and conditions of the Agreement, the Pledge Agreement and the Control Agreement shall remain unamended and unwaived and
shall continue to be, and shall remain, in full force and effect in accordance with their respective terms. The provisions set forth
herein shall be limited as provided for herein, and shall not be deemed to be a waiver of, amendment to, consent to or modification
of any other term or provision of the Agreement, the Pledge Agreement or the Control Agreement or of any event, condition or
transaction on the part of the Issuer or any other person that would require the consent of the Subscribers. The execution, delivery
and effectiveness of this Amendment shall not, by implication or otherwise, limit, impair, waive or otherwise affect any right,
power or remedy of any Subscriber under the Agreement, the Pledge Agreement or the Control Agreement. Each party hereto acknowledges
and agrees that the execution and delivery by the Subscribers of this Amendment shall not be deemed (i) to create a course of
dealing or otherwise obligate any Subscriber to forbear, waive, consent or execute similar amendments, agreements or waivers in the
future, or (ii) to amend, relinquish or impair any right of the matter arising from or relating to this Amendment.

 

2.4   Counterparts;
Headings; Jurisdiction and Governing Law; and Waiver of Jury Trial. The provisions of Sections 14(m), (n), (o), (p), (q) and (r) of
the Agreement shall apply mutatis mutandis to this Amendment.

 

[Signature Pages Follow]

 

    3 

     

    

 

IN
WITNESS WHEREOF, each Subscriber has executed or caused this Amendment to be executed by its duly authorized representative
as of the date set forth below.

 

	Name of Subscriber: Shaolin Capital Partners Master Fund
Ltd	State/Country of Formation or Domicile: Cayman Islands

 

	By:	Shaolin Capital Management LLC, its investment manager	 
	 	 	 
	 	 	Date: December 27, 2022
	 	 	 
	 	By: 	/s/ David Puritz	 
	 	 	 	 
	 	Name:	 David Puritz	 
	 	 	 	 
	 	Title:	Chief Investment Officer	 

 

 

    4 

     

    

 

 

	Name of Subscriber: MAP 214 Segregated Portfolio, a segregated
portfolio of LMA SPC	State/Country of Formation or Domicile: Cayman Islands

 

	By:	Shaolin Capital Management LLC, its advisor	 
	 	 	 
	 	 	Date: December 27, 2022
	 	 	 
	 	By:	/s/ David Puritz	 
	 	 	 	 
	 	Name:	David Puritz	 
	 	 	 	 
	 	Title:	Chief Investment Officer	 

 

    5 

     

    

 

	Name of Subscriber: DS Liquid DIV RVA SCM LLC	State/Country
of Formation or Domicile: Delaware, USA

 

	By	 FRM Investment Management (USA) LLC, its manager	 
	 	 	 
	 	 	Date: December 27, 2022
	 	 	 
	 	By:	/s/ Lisa Munoz	 
	 	 	 	 
	 	Name:	Lisa Munoz	 
	 	 	 	 
	 	Title:	Assistant Secretary	 

 

    6 

     

    

 

	Shaolin Capital Partners SP, a segregated portfolio of PC MAP SPC	State/Country of Formation or Domicile: Cayman Islands

 

	By:	Shaolin Capital Management LLC, its advisor	 
	 	 	 
	 	 	Date: December 27, 2022
	 	 	 
	 	By:	/s/ David Puritz	 
	 	 	 	 
	 	Name:	David Puritz	 
	 	 	 	 
	 	Title:	Chief Investment Officer	 

 

    7 

     

    

 

IN
WITNESS WHEREOF, the Issuer has accepted this Amendment as of the date set forth below.

 

	TH
INTERNATIONAL LIMITED	 	State/Country of Formation or Domicile: Cayman Islands
	 	 	 
	By:	/s/ Paul Hong	 	Date:
December 27, 2022 
	 	 	 	 
	Name: 	Paul Hong	 	 
	 	 	 	 
	Title:	Director	 	 

 

    8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]